Indications |
Ophthalmic Open-angle glaucoma Adult: Instill 1 drop of a 0.2% solution bid-tid. |
Contraindications |
Hypersensitivity. Patients receiving MAO inhibitor therapy. |
Warnings / Precautions |
Patients wearing soft contact lenses should wait for at least 15 min after instilling brimonidine tartrate before inserting soft contact lenses. Renal or hepatic impairment. CV disease. Use with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangitis obliterans. Pregnancy, lactation. |
Adverse Reactions |
Oral dryness; ocular hyperaemia, burning and stinging; headache, blurring of vision; foreign body sensation, fatigue or drowsiness; conjunctival follicles, ocular allergic reactions and ocular pruritus. Corneal staining or erosion, photophobia, eyelid erythema, ocular ache and pain, ocular dryness, tearing; upper respiratory symptoms; eyelid oedema, conjunctival oedema, dizziness, blepharitis, ocular irritation; GI symptoms; asthaenia; conjunctival blanching, abnormal vision and muscular pain. |
Drug Interactions |
Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with β-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines. See Below for More brimonidine Drug Interactions |
Mechanism of Actions |
Brimonidine is an α2-adrenoceptor agonist which works to reduce aqueous humor production and increase uveoscleral flow. |
Storage Conditions |
Ophthalmic: Store at 15-25°C. |
ATC Classification |
S01EA05 - brimonidine ; Belongs to the class of sympathomimetics used in the treatment of glaucoma. |
Storage |
Ophthalmic: Store at 15-25°C. |
Available As |
|
Brimonidine Tartrate
Post Review about Brimonidine Tartrate Click here to cancel reply.
Brimonidine Tartrate Containing Brands
Brimonidine Tartrate is used in following diseases
Drug - Drug Interactions of Brimonidine Tartrate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.